Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Initial results positive for insomnia trial
February 2016
EDIT CONNECT

SHARING OPTIONS:

WALTHAM, Mass.—A Phase 2a clinical trial on MIN-202 (JNJ-42847922) has yielded favorable top-line results for biopharmaceutical company Minerva Neurosciences Inc. The compound is a selective orexin-2 receptor antagonist under joint development with Janssen Pharmaceutica NV for insomnia disorder. Patients received either MIN-202 or placebo in a cross-over design for treatment periods of five days, separated by a washout period. Trial participants that received MIN-202 demonstrated statistically significant improvements in key sleep parameters, including sleep efficiency as measured by objective polysomnography, compared to those who received the placebo. No serious adverse events were observed, and preliminary data indicate that MIN-202 is well tolerated. The most common adverse events were somnolence and abnormal dreams. Minerva and Janssen began a co-development and license agreement in February 2014 for MIN-202 and any other orexin-2 compounds.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.